Navigation Links
DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Date:8/19/2007

SOMERSET, N.J., Aug. 9 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. ("DOV" or the "Company") (Pink Sheets: DOVP.PK) today announced Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor ("TRIP") for the treatment of depression and obesity. Preliminary analysis of the study results indicates DOV 21,947 was safe and well-tolerated at the doses examined and produced a significant decline in plasma triglyceride levels. The Company intends to initiate a Phase II study of DOV 21,947 for the treatment of depression in the fourth quarter of this year.

"Prior studies with DOV 21,947 at up to 100 mg per day demonstrated the safety and tolerability of this compound over dosing periods of up to ten days. The goal of this Phase Ib study was to confirm DOV 21,947's safety and tolerability over an eight-week period at escalating doses of up to 150 mg per day. These data give us added confidence in the drug's safety and tolerability in preparation for our upcoming Phase II trial in patients with major depressive disorder. The significant reductions in plasma triglyceride levels observed during the conduct of this study are consistent with preclinical evidence that DOV 21,947 is able to produce a significant and sustained reduction in both triglyceride levels and body weight in animal models of obesity. These findings underscore the therapeutic versatility of triple reuptake inhibitors such as DOV 21,947," said Dr. Phil Skolnick, President and Chief Scientific Officer of DOV.

This double-blind, placebo-controlled Phase Ib study enrolled 46 male and female subjects. Following a one-week placebo run-in, subjects received either escalating daily doses of 50 mg, 100 mg and 150 mg of DOV 21,947 (31 subjects) or placebo (15 subjects), for a total of eight weeks. The study demonstrated that DOV 21,947 was safe and well-tolerated in this dose range with no reported serious adverse events. The proportion of patients with treatment emergent adverse event
'/>"/>

SOURCE DOV Pharmaceutical, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 On Thursday, ... 0.52%, the Dow Jones Industrial Average finished the day 0.42% ... down 0.41%. The losses were broad based as eight out ... 500 Health Care Sector Index ended the day at 711.88, ... last one month. Investor-Edge has initiated coverage on the following ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI ... solutions, today announced that it will host its earnings ... a.m. Pacific Time (10:00 a.m. Eastern Time) to discuss ... quarter ended June 30, 2014. To access ... a.m. Pacific time on July 24, 2014.  The participant ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Inc. (Nasdaq: BIOD ) will issue its third ...  Following the release of the company,s financial results, Biodel,s senior ... and provide an update on the company,s progress.August 4, 2011 ... be distributed4:15 pm EDT: , Conference call participants should dial:+1 ...
... Reportlinker.com announces that a new market research ... Insulin- Western Europe ... package contains 14 insulin market analyses from ... Denmark, Finland, France, Germany, Ireland, Italy, the ...
Cached Medicine Technology:Insulin- Western Europe 2
(Date:7/11/2014)... Riverside Health System became the first provider of Community- ... and now, in partnership with Williamsburg Landing, will offer its ... Newport News region. , Also known as life care at ... adults who wish to remain in their homes but want ... services as well as control over the cost of long-term ...
(Date:7/11/2014)... scientists have been trying to unravel mechanisms that guide ... that generate all blood cells including our immune system. ... because they can only be found in the bone ... a culture dish. Now a group of scientists from ... (Technische Universitt Dresden) was able to generate a mouse ...
(Date:7/11/2014)... 2014 WWTrek Human Outreach Project ... Community in Tanzania. Opened in 2012, the KKC is now ... cows. HOP Founder, Dean Cardinale, started the KKC to create ... orphaned children he encountered while running treks on Tanzania's Mount ... who have all made astounding progress in school over the ...
(Date:7/11/2014)... Francisco shows that an "expressive therapy" group intervention ... with HIV disclose their health status and improves ... quality of their relationships., "Medication alone is totally ... Machtinger, MD, director of the Women,s HIV Program ... are on effective antiretroviral therapy but far too ...
(Date:7/11/2014)... 2014 Recently, iFitDress.com, a leading online ... has released its new collection of evening dresses ... has announced that all these beautiful items are provided ... of the special offer is July 22. , ... pay close attention to customer satisfaction. On the company’s ...
Breaking Medicine News(10 mins):Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Opening-up the stem cell niche 2Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2
... Windows Vista, Adobe Flash 10 and high-availability failover support. , ... ... today announced the release of the latest version of the industry ... of CoolSign further builds on its existing enterprise-based, robust feature set, ...
... 2009 As Zimbabwe continues to confront a,cholera ... a new,World Vision project supported by the Procter ... Drinking Water Program is underway, providing Zimbabweans with ... families and their,communities. , ...
... a limited edition beauty bag filled with products as ... Wash. and NEW YORK, Feb. 24 Beauty.com, Inc., ... DSCM ), announces Shoshanna Gruss as their ... program. Beginning February 25th, the exclusive Shoshanna-designed beauty case ...
... Them Crazy While They Work...30,000+ Dentists Converge in Chicago ... being issued by the Chicago Dental Society:Who: The ... members to find out some wacky, unusual, and just ... their chair.As we countdown to CDS,s annual Midwinter Meeting, ...
... dental techniques, , , TUESDAY, Feb. 24 (HealthDay News) -- ... and the development of skin and the nervous system ... University researchers have found. , Their discovery about the ... methods of repairing damaged enamel and preventing cavities, restoring ...
... promiscuity, experts stress, , , TUESDAY, Feb. 24 (HealthDay News) -- ... have sex, but a new study provides another suggestion that ... and teenage sexual activity. , The findings indicate that ... more likely to copy or emulate what they hear," said ...
Cached Medicine News:Health News:Procter & Gamble and World Vision Equip and Empower Zimbabweans in Fight Against Cholera 2Health News:Procter & Gamble and World Vision Equip and Empower Zimbabweans in Fight Against Cholera 3Health News:NY Fashion Designer Shoshanna Creates Exclusive Spring Bag for Beauty.com 2Health News:NY Fashion Designer Shoshanna Creates Exclusive Spring Bag for Beauty.com 3Health News:Top 5 Most Annoying Dental Patient Behaviors 2Health News:Scientists Find Gene for Tooth Enamel 2Health News:'Degrading' Lyrics Linked to Teen Sex 2Health News:'Degrading' Lyrics Linked to Teen Sex 3
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
... latest and most advanced fecal occult blood ... An immunochemical FOBT (iFOBT) with high specificity ... to detect bleeding associated with more cancers ... of its superior specificity for lower GI ...
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: